[Value of premedication with gonadotropin releasing hormone agonists before transcervical resection of solitary submucous myoma].
In a retrospective study, the value of pretreatment with a gonadotropin-releasing-hormone (GnRH) agonist before hysteroscopic myoma resection was assessed in 31 patients suffering from menorrhagia. No difference in operating time, intra-operative fluid deficit, blood loss and postoperative eumenorrhoea rate was found between pretreated and non-pretreated patients with solitary submucous myomas smaller than 4 cm in diameter. Thus, pretreatment with GnRH agonists before the resection of small solitary submucous myomas has no benefit for the patients.
Römer
T
T
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ernst-Moritz-Arndt-Universität, Greifswald, Deutschland.
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D004724:Endoscopy; D005260:Female; D006801:Humans; D015907:Hysteroscopy; D007889:Leiomyoma / Q000473:pathology / Q000601:surgery*; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008595:Menorrhagia / Q000473:pathology / Q000601:surgery; D011292:Premedication; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000473:pathology / Q000601:surgery*; D014599:Uterus / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide